On Tuesday, Shares of The Bank of New York Mellon Corporation (NYSE:BK), lost -3.67% to $38.34.
MT Newswires, a division of MidnightTrader, Inc., is happy to declare their agreement with Pershing LLC, a division of BNY Mellon (BK), to expand their existing relationship. The company presently provides its Live Briefs US Investor news across the NetXInvestor platform and will now provide its Live Briefs Investor North American news to all NetX360® clients. In addition, NetX360 clients will have the option to have access to the popular Live Briefs PRO North American newswire, which delivers original, real-time, multi-asset class coverage of US and Canadian markets with extensive coverage of developed capital markets and economies globally. With the addition of Live Briefs® PRO North America to their applications, NetX360 users, counting advisors, wealth managers and brokers, will enjoy a greatly improved news experience.
Pershing is a recognized leader in providing global financial solutions to their users, ranging from clearing and custody services, managed investment and practice administration solutions, to prime services, trading, retirement account, and technology and enterprise data administration solutions. Their clients worldwide comprise advisors, asset managers, broker-dealers, family offices, fund managers, registered investment advisor firms, and wealth managers. NetX360® is their digitally enabled professional platform, designed to assist users work more efficiently, onboard and collaborate with clients more effectively, and stay connected on the go.
The Bank of New York Mellon Corporation, an investment company, provides financial products and services to institutions, corporations, and high net worth individuals in the United States and internationally. It operates through two segments, Investment Administration and Investment Services.
Finally, Regulus Therapeutics Inc. (NASDAQ:RGLS), ended its last trade with -0.84% loss, and closed at $8.26.
Regulus Therapeutics declared the appointment of Michael Huang, M.D. as Vice President, Clinical Development. Dr. Huang is an practiced drug developer with proven success in advancing programs through clinical trials that led to commercialization in a wide range of therapeutic areas. At Regulus, Dr. Huang will be responsible for leading the company’s global clinical operations and medical affairs and will serve as a key member of the executive leadership team.
Most recently, Dr. Huang served as Vice President, Clinical Development of Auspex Pharmaceuticals, Inc. (attained by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders. Preceding to Auspex, Dr. Huang served in medical leadership roles at Santarus, Inc., Spectrum Pharmaceuticals, Inc., Phenomix Corporation and Valeant Pharmaceuticals International. His clinical and medical expertise has resulted in regulatory approvals of Potiga®, Zevalin®, Uceris® and Ruconest®. Dr. Huang received his Bachelor of Arts degree in molecular and cell biology from the University of California, Berkeley and an M.D. from the Chicago Medical School at Rosalind Franklin University. He accomplished his residency training in family medicine at the University of California, Irvine and is Board Certified in primary care medicine. Dr. Huang is the author or co-author of numerous peer-reviewed journal articles, abstracts and scientific publications.
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
